A systematic review and meta-analysis published on 29 August pooled nine randomised trials covering 6,239 adults with overweight or obesity but without diabetes, and found that injected semaglutide reduced a standard marker of inflammation by roughly 40% alongside the weight loss it is prescribed for. Serious adverse events were no more common than on placebo. For anyone weighing whether these drugs do anything beyond the number on the scale, this is a useful piece of the answer — with real limits on how far it can be read.
What was pooled, and what it found
The authors searched PubMed, the Cochrane Library and ClinicalTrials.gov for randomised trials comparing subcutaneous semaglutide against placebo in adults with overweight or obesity and no diabetes. Nine trials met the criteria. Across them, semaglutide produced a mean reduction in body weight of 12.04% (95% confidence interval −13.08 to −11.00) and in waist circumference of 9.36 cm (CI −10.27 to −8.45), both against placebo.
The inflammation result is the one that adds something new. C-reactive protein, a general marker of systemic inflammation routinely measured in cardiovascular risk assessment, fell by a mean of 40.90% (CI −46.37 to −35.42). All three results were significant at p < 0.00001, and the confidence intervals are narrow — the effect is consistent across the pooled trials rather than driven by one outlier.
On safety, the risk ratio for serious adverse events was 1.12 with a confidence interval of 0.76 to 1.65 (p = 0.55). That interval comfortably spans 1.0, meaning no significant difference from placebo was detected. It does not demonstrate equivalence — an interval that wide is also consistent with a modest real difference in either direction.
How much this actually tells you
A meta-analysis inherits the limits of its inputs. These were trials in adults without diabetes, so the findings do not transfer to people taking these drugs for type 2 diabetes. The CRP reduction is a change in a marker, not a demonstrated reduction in heart attacks or strokes; those are different endpoints requiring different trials. And CRP falls with weight loss generally, so this does not establish an anti-inflammatory effect independent of the weight lost.
The 12% average also sits below the roughly 15% reported in the STEP 1 trial. That is not a contradiction — pooling trials of differing lengths, doses and populations pulls the average down. It is a reminder that a single trial’s headline figure is close to a best case rather than a typical one, which matters if you are budgeting for a year of treatment. What the drugs cost over that year is set out in our pricing breakdown.
The authors note that the recently published STEP UP trial of a higher 7.2 mg dose showed greater weight reduction than previously available data, and call for longer-term studies to define efficacy and safety over time. That caveat is the honest position: most of this evidence runs to 68 weeks or less, and these are medicines people may take for years.
